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Background: Besides the classical role of vitamin D on calcium and bone homeostasis, vitamin D deficiency has
recently been identified as a contributing factor in the onset of insulin resistance in type 2 diabetes mellitus.
However, it is uncertain whether vitamin D deficiency and poor glycaemic control are causally interrelated or that
they constitute two independent features of type 2 diabetes mellitus. There are limited clinical trials carried out
which measured the effect of vitamin D supplementation on glycaemic control.
The objective of this study is to investigate the effect of vitamin D supplementation on glycaemic control and
quality of life in patients with type 2 diabetes mellitus.
Methods/design: In a randomised double-blind placebo-controlled trial conducted in five general practices in the
Netherlands three hundred patients with type 2 diabetes mellitus treated with lifestyle advises or metformin or
sulphonylurea-derivatives are randomised to receive either placebo or 50,000 IU Vitamin D3 at monthly intervals.
The primary outcome measure is the change in glycated haemoglobin level between baseline and six months.
Secondary outcome measures include blood pressure, anthropometric parameters, lipid profile, insulin resistance,
quality of life, advanced glycation end products and safety profiles. Quality of life will be measured by The Short
Form (SF-36) Health Survey questionnaire. Advanced glycation end products are measured by an AGE-reader.
Discussion: This trial will be the first study exploring the effect of vitamin D supplementation on both glycaemic
control and quality of life in patients with type 2 diabetes mellitus. Our findings will contribute to the knowledge of
the relationship between vitamin D status and insulin resistance in patients with type 2 diabetes mellitus.
Trial registration: The Netherlands trial register: NTR3154
Keywords: Vitamin D, Type 2 diabetes mellitus, Quality of life, Advanced glycation end products, Insulin resistanceBackground
Type 2 diabetes mellitus (T2DM), characterized by peripheral
insulin resistance and pancreatic beta-cell dysfunction, repre-
sents a worldwide epidemic with significant co-morbidity
and mortality due to microvascular and macrovascular
complications [1]. Although therapies for T2DM and its
co-morbidity have improved over the last few decades, the* Correspondence: s.simsek@mca.nl
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reproduction in any medium, provided the orneed for new insights for the prevention and management
of T2DM remains needed due to the increased impact of
the disease. There is accumulating evidence suggesting
that vitamin D status plays a role in many non-skeletal
functions including diabetes mellitus [2,3]. The prevalence
of vitamin D deficiency is increasing with an estimating
number of one billion people worldwide [3]. A recent
study in the Netherlands among older people revealed a
prevalence of vitamin D deficiency of 47.8% (defined as 25
(OH) D < 50 nmol/l) [4].
Vitamin D is a secosteroid that is obtained from diet-
ary sources, either food or supplements, and exposure toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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biologically active. Vitamin D is transported to the liver
where it is first hydroxylated by 25-hydroxylase into
25-hydroxyvitamin D (25 (OH) D). This is the major
circulating form used as an indicator of vitamin D sta-
tus. The second hydroxylation occurs in the kidney by
1α-hydroxylase (1α-OHase), a product of the CYP27B1.
Here the largest amount of the biologically active form
of vitamin D: 1,25 dihydroxyvitamin D (1,25 (OH) 2D) is
formed. Besides its classical role in calcium and bone
homeostasis, vitamin D deficiency has recently been iden-
tified as contributing factor in the onset of insulin resist-
ance in T2DM [5,6]. In a meta-analysis of observational
studies a relatively consistent association between low
vitamin D status and the prevalence of T2DM or meta-
bolic syndrome was reported [6]. However, due to con-
founding and selection bias in epidemiological studies, a
causal link cannot be established. To determine whether
the relation between vitamin D deficiency and glycaemic
control is causal in nature, randomised controlled trials
with vitamin D supplementation are needed. To date, only
few clinical trials examining this relation, with glycaemic
control as primary outcome in T2DM, have been per-
formed [7-13]. The results of these clinical trials are in-
consistent mostly due to the small sample size, low dose
of vitamin D supplementation and short duration of the
trials. Recently, a meta-analysis done by George et al. [14]
demonstrated a small effect of vitamin D supplementation
on fasting glucose and insulin resistance, with no effect on
HbA1c. However most of these reviewed studies did not
include diabetic patients nor had insulin resistance as pri-
mary outcome [15-22]. Therefore, adequately powered,
randomised placebo-controlled clinical trials with vitamin
D supplementation are needed.
The potential mechanisms by which vitamin D can
affect glucose metabolism could be the result of a rapid
non-genomic effect or slower genomic effect of serum
25 (OH) D: 1) stimulation of insulin release by the in-
creased expression of vitamin D receptor (VDR) as well
as the enzyme 1α-OHase in the pancreatic beta-cells; 2)
by binding of the 1,25 (OH) 2D - VDR complex to the
vitamin D response element of the insulin receptor at
tissue level enhancing insulin responsiveness for glucose
transport; 3) suppression of the release of pro-inflammatory
cytokines that are believed to mediate insulin resistance
[2,5,23]. The latter hypothesis is supported by studies show-
ing an association between low serum 25 (OH) D and in-
creased C-reactive protein levels [24]. Indirectly, vitamin D
may influence the extracellular and intracellular calcium
regulation which is essential in mediating glucose transport
in target tissues.
Another hypothesis may be the influence of serum
vitamin D on oxidative stress and thereby reducing the
formation of advanced glycaemic end products (AGEs).AGEs are a heterogeneous group of compounds formed
nonenzymatically by glycation and oxidation of proteins.
In patients with T2DM AGE formation is enhanced as a
consequence of a hyperglycaemic and free radical rich
environment [25]. The AGE accumulation in the skin, as
measured by skin autofluorescence, has found to be an
independent strong predictor of microvascular and
macrovascular complications in both type 1 and type 2
diabetes [26-28]. Until now, solely a study conducted in
diabetic rats is available which demonstrated a relation
between AGEs and vitamin D [29].
We proposed to start a RCT with the following objectives:
i. To investigate the effect of vitamin D
supplementation on glycaemic control and insulin
resistance in patients with T2DM.
ii. To investigate the effect of vitamin D
supplementation on health related quality of life
measured by SF-36 in patients with T2DM.
iii. To investigate the association between skin
autofluorescence and serum vitamin D
Methods/design
Study design
We designed a double-blind, randomised placebo-
controlled clinical trial among patients with T2DM. We
randomly assigned three hundred patients into 1:1 ratio
to receive a monthly dose of cholecalciferol 50,000 IU or
placebo. The follow-up duration is six months. The
study will be conducted in five general practices in and
around Alkmaar, a city in north-western Netherlands at
latitude 52°.
Participants
All patients with T2DM at the general practices fulfilling
the inclusion criteria at their last visit by the general prac-
titioner will be invited for screening for their eligibility.
Inclusion/exclusion criteria
Adults (≥18 years) with T2DM, diagnosed according to
the World Health Organisation, who are treated with
lifestyle advises, metformin, or sulfonylurea-derivatives
(SU-derivatives), whether or not in combination, were in-
vited for participation. Serum glycated hemoglobin (HbA1c)
had to be stable and below or equal to 64 mmol/mol
(8.0%) for the last three months without recent changes
in hypoglycaemic agents.
The exclusion criteria are: an impaired renal function
(estimated creatinine clearance < 30 ml/min measured by
the MDRD formula: 186 × (serum creatinine)^ −1.154 ×
(age)^ −0.203 × 0.742 (if the subject is female) or × 1.212
(if the subject is black)), any granuloma forming disorder,
known history of renal stones or hypercalcaemia (serum
calcium > 2.65 mmol/l), hypo- or hyperphosphatemia,
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tolerance for cholecalciferol, using other antidiabetic treat-
ment as mentioned above, insufficient knowledge of the
Dutch language, mental retardation or psychiatric treat-
ment for schizophrenia or bipolar disorder, participation
in any other trial, being pregnant or lactating, or no signed
informed consent.
Outcomes
The primary outcome of the study is HbA1c. Secondary
outcomes are insulin resistance and beta-cell function
measured by the homeostasis model of assessments
(HOMA) and quantitative insulin sensitivity check index
(QUICKI). Further secondary outcomes include the al-
teration of serum 25 (OH) D over time, blood pressure,
lipid profile, parathyroid hormone, calcium, thyroid
function, AGE accumulation in the skin, safety profile of
vitamin D supplementation, urine analysis for microal-
buminuria, and quality of life assessed by The Short
Form (SF-36) Health Survey questionnaire.
Sample size estimation
It was calculated that 126 patients with T2DM would be
required in this trial to demonstrate a significant differ-
ence at 80% power and 5% significance. Power calcula-
tions were based on the literature and aimed at a
difference of 0.5% in HbA1c value in the treated group
as compared to the placebo group with a standard devi-
ation of 1.0% [30]. With an expected rate of 50% vitamin
D deficient participants, 252 subjects would be required.
According to an expected drop out rate of 20%, 300 sub-
jects will be recruited.
Randomisation
A double-blind randomised placebo-controlled trial de-
sign has been chosen. Randomisation for the parallel
treatment phase will be carried out by the pharmaceutical
department after checking the inclusion- and exclusion
criteria. The patient will be assigned to the treatment
order as defined by the code. The patients will be rando-
mised 1:1 according to the method of block randomisa-
tion with a block size of 10. No stratification is used. The
study medication will be delivered in similar flagons and
labels with its own sequence number. The allocation se-
quence number will be kept by the pharmacist in a secure
place during the course of the study.
Intervention
In this trial the dose of vitamin D (cholecalciferol) being
supplemented is 50,000 IU. The consumption frequency
will be once a month (equivalent to ~1667 IU/day in the
treatment group) for six consecutive months. We chose
the oral route of administration. Cholecalciferol is sup-
plied in a vial of 8 ml containing 50,000 IU per ml,meaning the patients will use 1 ml per month. The pla-
cebo will be identical in taste, texture and appearance
as the active supplement. The vitamin D supplement
and placebo are manufactured and packed by the phar-
macy of the Meander Medical Centre, Amersfoort, the
Netherlands. Both the active supplements and the pla-
cebo will be given to participants in a translucent flagon
with only their sequence number on the label. Labeling
of the flagons will be done by the same person doing the
randomisation and allocation sequence. A pipette of
1 ml will be delivered by the vial to make sure all pa-
tients use the right dose of the study medication. During
their first visit patients will be instructed how to take in
the study medication correctly with the pipette. To en-
sure compliance during the study, reminders about the
intervention appointments will be sent regularly via
email of phone calls.
The safety of vitamin D supplementation has well been
established. The recommended dose for adults is 600–
800 IU/day, depending on age, with an upper limit of
4,000 IU/day [31]. Toxicity of vitamin D supplementation
did not occur with a dose of 10,000 IU/day [32]. Side ef-
fects (hypercalcaemia, hypercalcuria, renal stones, gastro-
intestinal symptoms or hypersensitivity symptoms) of
vitamin D supplementation are rare. For the safety of all
patients serum creatinine and calcium are measured at
three months. Patients with known hypercalcaemia are ex-
cluded for this reason. A 24 hour telephone number is
available in the case hypersensitivity symptoms occur.
Handling and storage of data and documents
For each participant a Case Record Form (CRF) is pro-
vided by the sponsor of the trial. All personal data are
stored on a coded drive which is only available to the
study coordination team. These documents will be
stored in the hospital for a minimum of ten years. The
Subject Identification Codes must be kept for at least
15 years. All these requirements are in accordance with
the ‘Wet Medisch Onderzoek met Mensen’.
Statistical analysis
The primary efficacy analysis to explore the intervention
effect on glycaemic control will be based on the intention-
to-treat (ITT) method, in which all randomised patients
for whom outcome data are available, will be recorded. In
the ITT analysis the patients will be analysed according to
their original group assignment, whether or not they ac-
cepted and/or adhered to the intervention. This analysis
avoids the possibility of any bias associated with loss,
misallocation or non-adherence of participants. If there
will be a substantial difference between those allocated
to receive an intervention and those who actually received
it (and adequately adhere to it), we will perform an additional
analysis adjusting for actual treatment received (‘per
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lysis will be compared with the ITT analysis and the
numbers involved will be precisely described.
All raw data will be entered into SPSS software (ver-
sion 20.0, SPSS Inc, Chicago, IL). Ten percent of all data
will be double-entered to check for duplication and out-
liers before starting statistical analyses.
Baseline characteristics of the study patients will be sum-
marised separately for each randomised group. Dichotom-
ous and categorical data will be presented as number and
percentages of patients within both groups. Continuous
variables will be checked for normality and will be pre-
sented in terms of means and standard deviation if
normally distributed, or when a variable has a skewed dis-
tribution as median, 25th and 75th percentiles. Nominal
variables including subgroups will be analysed using the
Chi-squared test, ordinal variables by the Mann-Witney
test or Kruskall-Wallis test and continuous variables by the
t-test or analysis of variance model (ANOVA).
The primary efficacy endpoint, HbA1c, will be com-
pared between placebo and treatment group using a re-
peated measures analysis of variance with adjustment for
baseline characteristics. For secondary outcomes a
paired t-test, Wilcoxon’s test or repeated measures ana-
lysis of variance will be performed. Delta values will be
calculated to compare the differences in means over
time between the treatment and placebo group.
Correlation coefficients will be measured using Pear-
son or Spearman, depending on the level of measure-
ment. A logistic and/or linear regression model will be
used for multivariate analysis to relate an outcome vari-
able to causal variables. The multivariate analysis will be
used to rule out the possible role of confounders for
vitamin D deficiency as season of measurement, mater-
nal age, ethnicity, diet, physical activity and BMI.
Subgroup analyses will be performed by stratifying vita-
min D into three groups: deficient (15–49 nmol/l), insuffi-
cient (50–74 nmol/l), and sufficient (75–150 nmol/l).
Furthermore, subgroup analyses for vitamin D deficient
patients (serum 25 (OH) D 15–35 nmol/l), and poor
glycaemic control (HbA1c ≥ 53 mmol/mol) will be per-
formed using the same method as described for the pri-
mary analysis. A p-value < 0.05 will be considered as
statistical significant.
Funding/ethics
This trial was approved by the Medical Ethics Commit-
tee of North-Holland, the Netherlands. No funding is
given for the trial.
Results
Study procedure
The study will be divided into two phases: Phase I and
Phase II.Phase I
Patients with T2DM who met the inclusion criteria at their
last visit at the general practice will be invited through a
brief introduction letter for participation. All patients will
be approached by phone in three weeks after receiving the
letter whether or not they are interested for participation.
If interested, the extensive patient information form will be
given and an appointment will be scheduled at the general
practice for informed consent and start of the trial.
Phase II
The trial has a total of three visits at the patient’s own gen-
eral practice (Figure 1). The initial visit includes informed
consent, assessment of eligibility, questionnaires regarding
demographics, sunlight exposure, physical activity, dietary
intake (fish and dairy products), diabetes history and
medication, co-morbidity and health related quality of life
(SF-36). Anthropometric parameters and skin AGE accu-
mulation will be measured. Blood collection will be collect
at this stage. The study medication will be given for six
months with a prior instruction. The second visit at three
months is for safety assessment and observation of con-
sumption. This includes: discussion of any adverse events,
any change in medication, control of the ingestion of the
study medication, blood collection (including serum cal-
cium, renal function, serum 25 (OH) D and HbA1c). The
final visit is at the end of six months, when questionnaires
and anthropometric measurements are repeated and the
last set of blood samples are collected (Table 1). The in-
clusion of all patients will be spread over one year to pre-
vent large seasonal influences, as well as the results will be
adjusted for seasonal influences.
All participants will be informed of their anthropometry
and blood pressure measurement at the start and during the
course of the trial. The blood test results during the course
of the trial will only be discussed when these are abnormal
and lead to premature termination of the trial. The follow-
ing criteria are drawn for premature termination of the
trial: hypercalcaemia (calcium > 2.65 mmol/l), onset of any
granuloma forming disease, serum 25 (OH) D < 15 nmol/l
or > 250 nmol/l, impaired renal function (eGFR < 30 ml/min),
hypersensitivity for cholecalciferol, onset of urolithiasis,
change in hypoglycaemic agents or HbA1c > 69 mmol/mol
(8.5%). After completion of the trial, all participants will
be informed of their blood results. In case of vitamin D
deficiency (serum 25 (OH) D < 50 nmol/l) at the end of the
trial, supplementation with cholecalciferol will be started.
The patients will be informed by letter in which group they
participated after every patient completed the trial.
Anthropometric parameters, AGE measurement and
health related questionnaire
Height and weight will be measured using a stadiometer
(up to 2 meters) and a weighing scale (200 kilograms).
Figure 1 Recruitment flow chart.
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clothes in the morning. Blood pressure will be measured
using a sphygmomanometer. The blood pressure will be
measured at the right arm whilst the patient is sitting
for at least 5 minutes. Tape-measurements will be per-
formed for waist and hip circumferences. Body Mass
Index (BMI) will be calculated by dividing weight through
the square of height. Waist to hip ratio will be calculated
by the formula: waist circumference/hip circumference.
The AGE accumulation in the skin will be measured
using an AGE reader (Diagnoptics Technologies B.V.,
Groningen, The Netherlands). This is a non-invasively de-
vice that can assess the tissue accumulation of AGEs using
fluorescence of ultraviolet light in human tissue. The fore-
arm is put on the machine and the concentration is
assessed by ultraviolet light. This procedure takes 3 mi-
nutes and will be done at baseline and at the final visit.
SF-36 health survey will be used to assess health-related
quality of life on emotional and physical wellbeing. Thepatients will receive the questionnaire at baseline and at
the end of the trial with a self-addressed envelope.
Blood collection
Venous blood sampling will be drawn at 0, 3 and 6 months
by registered staff nurses using a sterile vacutainer needle
between 8.00 and 9.30 am. All participants will be asked to
fast overnight for at least 8 hours before blood collection.
Blood serum will be used for the analysis of HbA1c,
C-peptide, fasting insulin, calcium, phosphate, albumin,
PTH, liver enzymes, lipid profile, C-reactive protein, TSH,
platelets count, leukocytes and hemoglobin and 25 (OH) D
((iSYS automated immunoanalyser (IDS GmbH, Frankfurt,
Germany)). The total 25-OH vitamin D assay detects 25-
OH VD3 and 25-OH VD2, both with a specificity of 100%.
The quality of the test is controlled by applying Westgard
QC-rules on 3 different QC-samples [33]. The accepted
interassay coefficients of variation are <10% for all 3 QC-
samples (low, medium and high level). TSH and intact-






Medical and family history x
Diet, sun exposure, physical activity x x
Advanced Glycation End products (AGEs) x x
Questionnaire SF-36 x x
Medication alterations x x
Adverse events x x
Anthropometry
Height, weight, BMI x x x
Blood pressure x x x
Waist/hip circumference x x
Blood analysis
Serum 25 (OH) D x x x
HbA1c x x x
Fasting blood glucose x x x
Fasting blood insulin x x x
C-peptide x x x
Serum creatinine x x x
Lipid profile x x
Serum calcium x x
Serum phosphate x x
Serum albumin x x x
Serum PTH x x
Serum TSH x x
AST x x
ALT x x
Alkaline phosphatase x x
γ-GT x x
Hb, Platelets, Leukocytes x x
C-reactive protein x x
Urine analysis x x x
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DxI 600 Synchron Access immunoanalyser (Beckman
Coulter Nederland B.V., Mijdrecht, the Netherlands).
Calcium, phosphate, glucose, albumin, liver enzymes, C-
reactive protein and lipid profiles will be determined on a
Beckman Coulter UniCel DxC 860i Synchron Clinical
system chemistry analyzer. C-peptide and insulin will be
determined on Siemens Immulite XPi automated immunoa-
nalyser (Siemens Medical Solutions Diagnostics B.V., Breda,
the Netherlands). HbA1c will be measured on a HA-8180automated HPLC system Menarini (Florence, Italy).
The total white blood cell count, platelets count and
haemoglobin content will be performed with an automated
Sysmex XE-2100 blood cell counter (Sysmex Coorperation,
Kobe, Japan).
Fasting blood glucose will be measured in blood plasma.
Homeostasis model assessment of insulin resistance
(HOMA-IR), calculated by fasting glucose (mmol/l) x fast-
ing insulin (IU/ml)/22,5 and QUICKI, calculated by 1/log
(fasting insulin (IU/ml)) + log (fasting glucose (mg/dl)),
will be used to evaluate insulin resistance. Pancreatic
beta-cell function will be assessed through the HOMA-B,
calculated by (20 x fasting insulin (IU/ml))/(fasting glu-
cose (mmol/l) – 3,5). All assays will be performed ac-
cording to the manufacturer’s instructions and carried
out by the central chemical laboratory of the Medical
Centre Alkmaar, the Netherlands. This laboratory is a
certified CCK laboratory. Aliquots of serum and plasma
will be stored at −70/80’C for future research questions.
Adverse events
All serious adverse events (SAEs) will be reported
through the web portal ToetsingOnline to the accredited
Medical Ethics Committee that approved the protocol,
within 15 days after the sponsor has first knowledge of
the serious adverse reaction. SAEs that result in death or
are life threatening episodes should be reported expe-
dited. The expedited reporting will occur not later than
7 days after the responsible investigator has first know-
ledge of the adverse reaction. This is for a preliminary
report with another 8 days for completion of the report.
Discussion
The main purpose of this study is to measure the effect
of vitamin D supplementation on glycaemic control and
health related quality of life in patients with T2DM.
There is widespread interest in the potential causal role
of vitamin D on the pathogenesis and progression of
T2DM. We hope this study will give new insight into
this causality. Until now conflicting results are seen in
observational studies and the few clinical trials per-
formed, which could not confirm a causal association
[7-14]. Factors for the lack of effect found in these stud-
ies includes: short trial duration, relatively low doses of
vitamin D supplementation whether or not combined
with calcium supplements, and heterogeneous study
populations.
This trial has several strengths: the study sample size
allows us to perform a subgroup analysis of vitamin D
deficient patients. Taken into account that only in vita-
min D deficient patients an effect of vitamin D supple-
mentation on glycaemic control will be found, we chose
to recruit double the number of participants as calcu-
lated with the power estimation, hypothesizing that 50%
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(serum 25 (OH) D < 50 nmol/l). Secondary, the rela-
tively high dose chosen for intervention and the duration
of the trial are strengths of our study. The dose of vita-
min D supplementation of 50,000 IU of vitamin D per
month (daily equivalent ~1667 IU) is based on the rec-
ommendations of the Institute of Medicine and on the
study done by van Groningen et al. [31,34]. In this latter
study, performed in the Netherlands, it was demon-
strated that a cumulative dose of 100,000 IU given in
2 months increases the serum 25 (OH) D meanly with
29 nmol/l. Assuming that the mean serum 25 (OH) D in
our study population will be around 50 nmol/l at base-
line, the serum 25 (OH) D should be raising to a suffi-
cient status (≥75 nmol/l) in two months. To measure a
difference in HbA1c level we hypothesize that the max-
imal effect will be seen at least at six months, regarding
the fact that the red blood cells circulate about 100 days
in the blood and HbA1c levels takes around six weeks to
change. Furthermore, this is the first study examining
the association between vitamin D status and skin auto-
fluorescence value as well as the effect on skin AGEs
after vitamin D supplementation. For this secondary out-
come the duration of our trial will be a limitation, re-
garding the stability and long half-life of skin AGEs with
could be the cause to find no effect of vitamin D supple-
mentation on skin AGEs.
The results of this trial should provide more insight
into the potential causal association between vitamin D
status and glycaemic control in patients with T2DM.Trial status
This study is in the process of participant recruitment.
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